1 / 3

PharmaDecisions: Empowering Fact-Based Decisions in Pharma & Biotech

Proven market analytics for new products, biomarker positioning, and portfolio planning. Fact-based decision support integrating IMS and SDI data analytics. Impact assessment of diagnostic markers on medicines, responder/non-responder segmentation, and safety markers analysis. Strategic situation analysis, market trends, competitive landscape evaluation, and unmet needs identification. Leveraging innovative methods to gather insights from key stakeholders.

prescott-houston
Download Presentation

PharmaDecisions: Empowering Fact-Based Decisions in Pharma & Biotech

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. ~PharmaDecisions powers fact-based decisions~ • Proven market analytics for pharma and biotech new product, indication prioritization, biomarker positioning and portfolio planning • Fact-based decision support using innovative, cost effective analytic tools:IMS and SDI data analytics integrated with physician and patient survey feedback • Preparation of situation analyses, business plans • Manage KOL, qualitative and quantitative market research input to forecast scenarios contact barbara@pharmadecisons.net

  2. ~PharmaDecisions powers fact-based decisions~ • Impact of Diagnostic Markers • Assess the value, usage, and reimbursement impact of diagnostic markers on new medicines • Responder/non-responder segmentation • Safety markers: determination of at-risk population • Assess potential of R&D companion diagnostics for consumer and point-of-care

  3. ~PharmaDecisions powers fact-based decisions~ • Situation analysis and recommendations • Market overview and trends • Epidemiology and demographics • Competitive landscape: current and emerging ongoing red flag CI alerts for game changers • Clinical protocols and endpoints • Unmet needs and target product profile assessments by stakeholders • physicians, patients, laboratories, reimbursers, KOL’s using cost-effective and innovative methods • Insight from physicians, patients, formulary decision-makers using cost-effective, innovative methods

More Related